Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.

Laith J Abu-Raddad ; Hiam Chemaitelly

; Houssein H Ayoub ; Hadi M Yassine ; Fatiha M Benslimane ; Hebah A Al Khatib ; Patrick Tang ; Mohammad R Hasan ; Peter Coyle ; Sawsan AlMukdad ; +14 more... Zaina Al Kanaani ; Einas Al Kuwari ; Andrew Jeremijenko ; Anvar Hassan Kaleeckal ; Ali Nizar Latif ; Riyazuddin Mohammad Shaik ; Hanan F Abdul Rahim ; Gheyath K Nasrallah ; Mohamed Ghaith Al Kuwari ; Adeel A Butt ; Hamad Eid Al Romaihi ; Mohamed H Al-Thani ; Abdullatif Al Khal ; Roberto Bertollini ; (2021) Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1). e1188-e1191. ISSN 1058-4838 DOI: 10.1093/cid/ciab909

Copy

Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.